Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents

…, JE Bajacan, AC Richardson, JL Ware, Y Zhang

Index: Zhang, Feng; Arnatt, Christopher K.; Haney, Kendra M.; Fang, Harrison C.; Bajacan, John E.; Zhang, Yan; Richardson, Amanda C.; Ware, Joy L. European Journal of Medicinal Chemistry, 2012 , vol. 55, p. 395 - 408,14 Title/Abstract Full Text Show Details Zhang, Feng; Arnatt, Christopher K.; Haney, Kendra M.; Fang, Harrison C.; Bajacan, John E.; Richardson, Amanda C.; Ware, Joy L.; Zhang, Yan European Journal of Medicinal Chemistry, 2012 , vol. 55, p. 395 - 408

Full Text: HTML

Citation Number: 6

Abstract

Recent studies have indicated that the CCR5 chemokine receptor may be a potential target for treating prostate cancer. Thus, development of CCR5 antagonists may provide novel prostate cancer therapy. Anibamine, a novel pyridine quaternary alkaloid isolated from Aniba sp., was found to effectively compete with 125I-gp120 in binding to the chemokine receptor CCR5, with an IC50= 1 μM. Anibamine is the first natural product reported as a ...